Module	GeneSet	RatioOfProteinInGeneSet	NumberOfProteinInGeneSet	ProteinFromModule	P-value	FDR	Nodes
0	Nicotinic acetylcholine receptor signaling pathway(P)	0.0066	50	4	0.0001	1.90e-02	ACTG1,MYO1C,MYO1D,MYO19
0	Regulation of actin cytoskeleton(K)	0.0286	215	6	0.0003	2.95e-02	SSH2,ITGB4,ACTG1,SOS2,BAIAP2,CRK
0	Arrhythmogenic right ventricular cardiomyopathy (ARVC)(K)	0.0100	75	4	0.0003	2.17e-02	DAG1,ITGB4,ACTG1,JUP
0	Arf6 trafficking events(N)	0.0185	139	5	0.0003	1.08e-02	EXOC7,CLTC,PLD2,JUP,CRK
0	Arf6 signaling events(N)	0.0185	139	5	0.0003	1.08e-02	EXOC7,CLTC,PLD2,JUP,CRK
0	Insulin Pathway(N)	0.0185	139	5	0.0003	1.08e-02	EXOC7,CLTC,PLD2,JUP,CRK
0	EGFR1(C)	0.0198	149	5	0.0004	1.21e-02	PITPNA,SOS2,PLD2,HTT,CRK
0	IGF1 pathway(N)	0.0199	150	5	0.0004	1.14e-02	EXOC7,CLTC,PLD2,JUP,CRK
0	Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met)(N)	0.0225	169	5	0.0007	1.81e-02	EXOC7,CLTC,PLD2,JUP,CRK
0	Syndecan-1-mediated signaling events(N)	0.0235	177	5	0.0009	2.16e-02	EXOC7,CLTC,PLD2,JUP,CRK
0	Focal adhesion(K)	0.0266	200	5	0.0015	3.54e-02	ITGB4,ACTG1,SOS2,FLNB,CRK
0	Integrin signalling pathway(P)	0.0277	208	5	0.0017	3.98e-02	ITGB4,ACTG1,SOS2,FLNB,CRK
1	Fatty acid metabolism(K)	0.0056	42	4	0.0000	3.00e-03	ACOX1,ALDH3A2,CPT1B,ACAA1
2	M Phase(R)	0.0128	96	6	0.0000	<1.00e-03	PAFAH1B1,FAM33A,TAOK1,BIRC5,MIS12,NDEL1
3	Homologous recombination(K)	0.0037	28	5	0.0000	<1.00e-03	XRCC3,RPA1,RAD51L1,TOP3A,RAD51L3
4	Wnt signaling pathway(P)	0.0425	320	8	0.0000	<1.00e-03	CTBP2,CELSR1,PCDHGA3,PCDHGA2,SMARCD2,SMARCE1,FAT1,TBL1X
4	Cadherin signaling pathway(P)	0.0181	136	4	0.0001	1.80e-02	CELSR1,PCDHGA3,PCDHGA2,FAT1
4	chromatin remodeling by hswi/snf atp-dependent complexes(B)	0.0021	16	2	0.0005	4.27e-02	POLR1D,SMARCE1
5	Signaling by Wnt(R)	0.0077	58	3	0.0000	6.00e-03	CSNK1A1,PSMC5,PSMB3
5	APC/C-mediated degradation of cell cycle proteins(R)	0.0100	75	3	0.0001	4.50e-03	PSMC5,PSMB3,CDC27
5	Cell Cycle Checkpoints(R)	0.0146	110	3	0.0002	1.00e-02	PSMC5,PSMB3,CDC27
5	Host Interactions of HIV factors(R)	0.0160	120	3	0.0002	1.00e-02	AP2B1,PSMC5,PSMB3
5	Proteasome(K)	0.0064	48	2	0.0011	3.64e-02	PSMC5,PSMB3
5	M/G1 Transition(R)	0.0081	61	2	0.0018	4.33e-02	PSMC5,PSMB3
6	SNARE interactions in vesicular transport(K)	0.0048	36	4	0.0000	<1.00e-03	SNAP29,STX8,GOSR2,GOSR1
6	Arf1 pathway(N)	0.0024	18	3	0.0000	<5.00e-04	GBF1,GOSR2,GGA3
6	Arf6 downstream pathway(N)	0.0039	29	3	0.0000	3.33e-04	GBF1,GOSR2,GGA3
6	Arf6 signaling events(N)	0.0185	139	3	0.0002	6.50e-03	GBF1,GOSR2,GGA3
6	Arf6 trafficking events(N)	0.0185	139	3	0.0002	6.50e-03	GBF1,GOSR2,GGA3
6	Insulin Pathway(N)	0.0185	139	3	0.0002	6.50e-03	GBF1,GOSR2,GGA3
6	IGF1 pathway(N)	0.0199	150	3	0.0003	7.14e-03	GBF1,GOSR2,GGA3
6	Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met)(N)	0.0225	169	3	0.0004	8.25e-03	GBF1,GOSR2,GGA3
6	Syndecan-1-mediated signaling events(N)	0.0235	177	3	0.0004	8.56e-03	GBF1,GOSR2,GGA3
6	Membrane Trafficking(R)	0.0055	41	2	0.0006	1.01e-02	STX8,GBF1
6	Class I PI3K signaling events(N)	0.0334	251	3	0.0012	1.51e-02	GBF1,GOSR2,GGA3
6	Proteogylcan syndecan-mediated signaling events(N)	0.0355	267	3	0.0014	1.62e-02	GBF1,GOSR2,GGA3
6	Plasma membrane estrogen receptor signaling(N)	0.0412	310	3	0.0022	2.08e-02	GBF1,GOSR2,GGA3
6	TRAIL signaling pathway(N)	0.0429	323	3	0.0024	2.15e-02	GBF1,GOSR2,GGA3
6	Glypican 1 network(N)	0.0580	436	3	0.0057	4.33e-02	GBF1,GOSR2,GGA3